GlassScriptPhysician profile
Sarah E Beaton
NPI 1043419021
$9,817.41
in general payments reported to CMS, 2019-2025
20 companies · $2,259 in 2025
The $2,259 reported for 2025 was more than what 92% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,339 · 2022: $2,081 · 2023: $2,126 · 2024: $2,013 · 2025: $2,259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,388 · Education: $9.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,388.12 |
| Education | $9.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,087.84 | 2022-2025 | |
| Lilly USA, LLC | $1,187.67 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Regeneron Healthcare Solutions, INC. | $1,084.61 | 2021-2025 | Dupixent |
| Leo Pharma INC. | $929.46 | 2021-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $836.82 | 2021-2025 | |
| Ucb, INC. | $572.31 | 2021-2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $509.15 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $496.14 | 2021-2025 | Nemluvio |
| Amgen INC. | $485.99 | 2021-2025 | Otezla, Otezla |
| Janssen Biotech, INC. | $376.38 | 2021-2025 | Stelara, Simponi, Simponi Aria |
| Sun Pharmaceutical Industries INC. | $289.94 | 2021-2025 | Ilumya, Winlevi |
| Novartis Pharmaceuticals Corporation | $263.37 | 2021-2025 | |
| Incyte Corporation | $230.20 | 2022-2024 | Opzelura |
| Pfizer INC. | $226.41 | 2022-2025 | |
| Organon LLC | $104.21 | 2025 | Vtama, Nexplanon |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $44.06 | 2021-2024 | Xolair |
| Kyowa Kirin, INC. | $29.97 | 2025 | |
| Arcutis Biotherapeutics, INC. | $24.69 | 2023 | |
| Sandoz INC. | $24.57 | 2024 | Hyrimoz |
| Biofrontera INC. | $13.62 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Beaton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.